| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02795884 Details | 2016-12-30 Interventional | 3 | 0 | Cisplatin Erlotinib Hydro… Pemetrexed Vinorelbine NSCLC | Because of reconsideration of using erlotinib(EGFR Tyrosine kinase inhibitor) as adjuvant aim - | |||
| NCT01167192 Details | 2016-12-30 Interventional | 2 | 10 | Carboplatin Breast Neoplasm… Triple Negative… | - - | |||
| NCT00891995 NCT00505206 Details | 2016-12-30 Interventional | 2/3 | [1 Refs] | 71 | Insulin Diabetes Mellit… Diabetes Mellit… Type 1 Diabetes | Primary outcome evaluation determined lack of treatment group difference - | ||
| NCT01984255 Details | 2016-12-29 Interventional | 1 | 3 | Bavituximab Ipilimumab Melanoma | standard of care improved combination treatment of ipilimumab plus nivolumab. - | |||
| NCT01710228 Details | 2016-12-29 Interventional | 2 | 0 | Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Multiple Sclero… Multiple Sclero… | sponsor stopped - | |||
| NCT00362869 Details | 2016-12-26 Interventional | 1 | 5 | Levofloxacin Escherichia col… Escherichia Col… | - - | |||
| NCT01816789 Details | 2016-12-23 Interventional | 4 | 194 | Buserelin In Vitro Fertil… Ovarian Stimula… | Optimal response: 63% nomogram, 42% controls, overcoming the stopping rule for interim analysis - | |||
| NCT02396030 Details | 2016-12-20 Interventional | 4 | 62 | Magnesium Sulfa… Pre-Eclampsia Preeclampsia | After recommendation because of the impossibility to end study with 1 center only. Outcomes of
patients already included will be evaluated. - | |||
| NCT02997059 2008-000717-30 Details | 2016-12-19 Interventional | 2 | 35 | Fluconazole Crohn Disease Crohn's Disease… | Limited recourse to intestinal resection due to new management of CD - | |||
| NCT00977145 Details | 2016-12-16 Interventional | 1 | 11 | Interferon-gamm… Melanoma | Closed short of the enrollment goal, due to slow enrollment and adequate data to address
endpoints - | |||
| NCT01600053 Details | 2016-12-15 Interventional | 2 | 11 | Lenalidomide Leukemia Leukemia, Lymph… Leukemia, Lymph… Chronic Lymphoc… | interim analysis showed that the trial will not meet the interim endpoint. - | |||
| NCT00081224 Details | 2016-12-15 Interventional | 2 | 3 | Capecitabine Celecoxib Adenocarcinoma Colorectal Canc… | - - | |||
| NCT00068666 Details | 2016-12-15 Interventional | 2 | [1 Refs] | 41 | Temozolomide Melanoma Melanoma (Skin) Metastatic Canc… | - - | ||
| NCT01410565 Details | 2016-12-13 Interventional | 3 | 66 | Apaziquone Non-Muscle Inva… Urinary Bladder… Bladder Cancer | Business reason - | |||
| NCT00352755 Details | 2016-12-13 Interventional | 2 | 18 | Fluorouracil Leucovorin Oxaliplatin Carcinoma Peritoneal Neop… Pseudomyxoma Pe… | after interim analysis it was determined that the risks were too great in comparision to the
results - | |||
| NCT00352690 Details | 2016-12-12 Interventional | 2 | 10 | Carboplatin Paclitaxel Paclitaxel poli… Carcinoma, Non-… | Safety of patients (3) grade 5 serious adverse events occurred and led to the study closing early for the safety of participants. | |||
| NCT02125266 Details | 2016-12-09 Interventional | 1/2 | 7 | Methotrexate Pars Planitis Uveitis Uveitis, Interm… Uveitis, Poster… | Study terminated due to unacceptable frequency of drug related adverse events - | |||
| NCT01324635 Details | 2016-12-09 Interventional | 1 | 17 | Histone Deacety… Panobinostat Brain Neoplasms Meningioma Neoplasm Metast… Brain Metastasi… High-grade Meni… Recurrent Gliom… | Arm A - reached goal; Arm B - poor accrual - | |||
| NCT02035345 Details | 2016-12-08 Interventional | 4 | 15 | Carboplatin Carcinoma, Ovar… Hypersensitivit… Ovarian Neoplas… Platinum Sensit… Recurrent Ovari… | Extended Carboplatin Infusion did not Reduce Frequency of Hypersensitivity Reactions - | |||
| NCT02631473 Details | 2016-12-07 Interventional | 1 | - | Efavirenz Lopinavir Ritonavir HIV | Study is on hold whilst a grant application for further funding is put together - |